



Enfermedades Infecciosas y Microbiología Clínica

www.elsevier.es/eimc



Original article

Hepatitis C prevalence among the migrant population in Spain: A systematic review and meta-analysis



Jeffrey V. Lazarus^a, Daniel J. Bromberg^a, Julia del Amo^b, Ole Norgaard^c, Javier García-Samaniego^d, Aina Casellas^a, José Luis Calleja^e, Ana Requena-Méndez^{a,*}

^a Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain

^b National Centre of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain

^c Scias, Copenhagen, Denmark

^d Liver Unit, Hospital Universitario La Paz, CIBERehd, IdiPAZ, Madrid, Spain

^e Hospital U Puerta de Hierro, IDIPHIM CIBERehd, Madrid, Spain

ARTICLE INFO

Article history:

Received 9 February 2018

Accepted 11 April 2018

Available online 30 May 2018

Keywords:

Hepatitis C

Migrant

Prevalence

Spain

Systematic review

Meta-analysis

ABSTRACT

Introduction: Spain, which has one of the largest migrant populations in Europe, has committed to eliminating the hepatitis C virus (HCV). The aim of this study was to estimate the prevalence of HCV among migrant groups in Spain, a country of 46 million people, with an estimated HCV-antibody prevalence of 1.7%.

Methods: Studies on HCV and migration in Spain were identified by systematically searching three databases from the first records to 30 November 2017, and consulting experts at the Ministry of Health and in the 17 Spanish autonomous communities. A meta-analysis was conducted to determine pooled HCV prevalence for the general migrant population. Prevalences were also calculated for high-risk migrant populations and populations who had undergone hospital screening, stratified by region of origin.

Results: Out of 243 studies identified, 26 met the eligibility criteria. The meta-analysis of the general migrant population found HCV antibody prevalence to be 1.6%. Migrants originating from European countries, including those at high or moderate risk for HCV, had the highest pooled prevalence (7.1%). In the general migrant population, prevalence was highest among sub-Saharan African migrants (3.1%) and lowest among Latin American migrants (0.2%).

Conclusion: Based on the limited available data, the prevalence among the general migrant population was found to be the same as the general Spanish population. Further research is needed to more accurately determine HCV prevalence for the overall migrant population and specific migrant subpopulations with a higher risk in the country as a whole and in each of Spain's 17 autonomous communities.

© 2018 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

Prevalencia de la hepatitis C en la población inmigrante española: revisión sistemática y metaanálisis

RESUMEN

Introducción: España, con una de las mayores poblaciones de inmigrantes en Europa se ha comprometido en la tarea de eliminar el virus de la hepatitis C (VHC). El objetivo de este estudio fue estimar la prevalencia del VHC entre los grupos de migrantes en España, un país de 46 millones de personas, con una prevalencia estimada de anticuerpos contra el VHC del 1,7%.

Métodos: Se identificaron los estudios sobre el VHC y la migración en España mediante la búsqueda sistemática de 3 bases de datos desde los primeros registros hasta el 30 de noviembre de 2017. Se consultaron expertos del Ministerio de Salud y de las 17 comunidades autónomas españolas. Se realizó un metaanálisis para determinar la prevalencia combinada del VHC para la población migrante general. También se calcularon las prevalencias para poblaciones migrantes de alto riesgo, y para aquellas poblaciones con cribado realizado a nivel hospitalario, estratificadas por región de origen.

Palabras clave:

Hepatitis C

Migrante

Prevalencia

España

Revisión sistemática

Metaanálisis

* Corresponding author.

E-mail address: ana.requena@isglobal.org (A. Requena-Méndez).

Resultados: De 243 estudios identificados, 26 cumplieron con los criterios de elegibilidad. El metaanálisis de la población migrante general encontró que la prevalencia de anticuerpos contra el VHC era del 1,6%. Los migrantes provenientes de países europeos, incluidos aquellos con alto o mediano riesgo del VHC, tuvieron la mayor prevalencia combinada (7,1%). En la población migrante general, la prevalencia fue más alta entre los migrantes del África subsahariana (3,1%) y más baja entre los migrantes de América Latina (0,2%).

Conclusión: En función de los datos disponibles que son limitados, el estudio muestra que la prevalencia entre la población general migrante en España es la misma que la de la población general española. Se necesitan más estudios para determinar con mayor precisión la prevalencia del VHC en la población general de migrantes y las subpoblaciones de población inmigrante con mayor riesgo específicas en el país en su conjunto y en las 17 comunidades autónomas de España.

© 2018 Elsevier España, S.L.U. y Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Todos los derechos reservados.

Introduction

The International Organization for Migration defines a migrant as “any person who is moving or has moved across an international border or within a State away from his/her habitual place of residence”.¹ Migrants are a diverse population, and the mechanisms of migration are complex and multifaceted. Some migrants are drawn to the real or perceived benefits of a new country, while others are forced to flee their countries of origin because of oppressive economic, political or social situations.^{2,3}

As of 1 January 2016, there were 35.1 million voluntary migrants and forcibly displaced persons living in the European Union.^{4,5} With 13% of its population foreign-born,⁶ Spain has the largest migrant population in Europe’s Mediterranean region. More than half of all migrants in Spain originate from six countries: Romania, Morocco, the United Kingdom, Italy, Ecuador and China, respectively.⁷

In 2017, there were an estimated 71 million people chronically infected with hepatitis C virus (HCV) worldwide.^{8,9} However, data on HCV prevalence in migrants remain scarce. Some countries have reported relatively high HCV rates among their migrant populations.¹⁰ The surge of migrants to Europe in 2015 raised concerns about their HCV status, given recent global commitments to combat and eliminate the disease.^{11,12}

The WHO Regional Office for Europe has encouraged Member States to prioritise access to health services for refugees and migrants.¹³ However, a lack of HCV prevalence data in the region limits the ability of health systems to monitor the disease burden and provide quality services to the most affected. National HCV surveillance systems have not been fully implemented in most of the region¹⁴ and data are particularly lacking for migrant populations.^{11,15} Furthermore, many European countries have inadequate national systems for registering migrants. This compounds the challenge of determining the HCV disease burden in migrant populations.¹⁶

It has been estimated that 90,000 people infected HCV immigrated to Spain between 1993 and 2008, based on an HCV serological test.¹⁷ Although there has been research involving this population,^{17–19} some of the studies did not specifically target migrants²⁰ or were only carried out in high-risk populations.²¹

With the advent of direct-acting antivirals in 2013, hepatitis C became readily curable.²² And in 2016, the World Health Organization (WHO) released its first *Global health sector strategy on hepatitis 2016–2021*, which calls for the elimination of viral hepatitis as a public health threat. In order to reach the strategy’s targets, it is crucial to identify which groups are at higher risk for the infection. The further scale-up of HCV testing in these groups can accelerate efforts to link more people to care and treatment, consequently reducing the burden of HCV disease.

In 2015, Spain approved an ambitious national hepatitis C strategy plan that recognises the public health importance of caring and

treating migrant groups.²³ The aim of this review and meta-analysis is to estimate the prevalence of HCV-antibodies among the migrant population in Spain, thereby contributing to informed decision-making around Spanish efforts to achieve HCV elimination.

Methods

The methodology was structured following the Meta-Analyses and Systematic Reviews of Observational Studies (MOOSE) guidelines.²⁴

Three bibliographic databases were systematically searched for studies on HCV and migration in Spain: MEDLINE (via Ovid), Embase (via Ovid) and CINAHL (via EBSCOhost). Each was searched from inception to 30 November 2017. Searches were conducted by combining the following three groups of terms: (1) hepatitis C, hepacivirus, hep C, HCV; (2) migration, migrants, transients, emigrants, migrants, refugees, displaced persons; and (3) Spain, Spanish ([Annex 1, supplementary material](#)). The search string was compared to a longer one that included the names of all autonomous communities of Spain and was found to yield the same results. Authors of recently published abstracts and manuscripts in press were contacted to retrieve full articles.

This search was supplemented by reviewing online sources from the Spanish Ministry of Health and regional health agencies/ministries in each of the 17 autonomous communities of Spain. Finally, national public health officers and the 17 regional health agencies/ministries were contacted twice (December 2016 and January 2017) to obtain additional documents reporting HCV prevalence in migrants.

Results were limited to include only findings involving humans. No restriction was applied to study design or language of publication. After removal of duplicates, the abstracts of the remaining records were screened to identify potentially relevant studies. Those studies then were manually screened to identify studies for inclusion in the final analysis.

Studies were eligible for inclusion if they met all of the following five criteria: (1) they reported the prevalence of HCV, defined as the presence of HCV antibodies; (2) they focused on Spain or at least one of its autonomous communities; (3) they reported on migrant populations; (4) they were primary sources of quantitative data; and (5) they were published after 1 June 2004. (Commentaries, editorials, letters and narrative reviews were excluded.)

All studies were assessed for quality using the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies from the United States National Institutes for Health.²⁵ The following data elements were extracted by two reviewers from the final set of studies: bibliographic details, Spanish autonomous community where the study took place, study year, methodology, target population, median age of study participants, serological test used to determine HCV status, HCV antibody prevalence, sample size

of study population and continent of origin of study participants. When continent-of-origin data were not available for everyone tested in a study, the prevalence data were designated “continent of origin not reported”. Disagreements between the two reviewers were resolved through discussion or, when necessary, consultation with a third author.

Data were extracted and HCV antibody prevalence was stratified, when possible, by continent of origin, the autonomous

community where the study was conducted and risk level of the study population. Risk level was defined using the following criteria: study participants tested in the community, primary care settings, maternity wards or blood banks were categorised as “general migrant population”. Those tested in hospitals or tropical medicine clinics were categorised as “hospital-based studies” and participants in studies that focused specifically on people who inject drugs, people living with




Fig. 1. Prisma flow diagram of the literature search.

HIV, sex workers and prisoners were categorised as “high-risk”.

Hospital-based studies and studies undertaken in high-risk populations were not excluded during data extraction. However, the pooled prevalence was calculated using only data from studies of general migrant populations. HCV prevalence in high-risk groups was reported in order to make comparisons to high-risk groups among the non-migrant population.

To conduct the meta-analysis, the Freeman-Turkey double arcsine transformation was used to calculate pooled-prevalence estimates, with corresponding 95% confidence intervals (CI).²⁶ A DerSimonian and Laird random-effects model was utilised and a Cochran's *Q* statistic was adopted to estimate heterogeneity between studies.^{27,28} The *I*² index was also reported, indicating the variation between studies attributed to heterogeneity rather than chance. Where heterogeneity was found not to be statistically significant, pooled prevalence estimates were calculated based on inverse variance from a fixed-effect model. Point prevalence and 95% CI from individual studies as well as pooled prevalence estimates and 95% CI for all strata are presented in the forest plot. Two-tailed tests were used for all analyses. Stata 15 was used for all analyses.²⁹

Results

The literature search yielded 243 potential articles after duplicates were removed. After screening by title and abstract, 46 articles remained (Fig. 1). An additional 24 articles were removed following full-article screening, resulting in 22 records. The main reasons for exclusion were case reports or case series, studies not reporting data on HCV, studies not reporting prevalence data, data not reported from Spain or data not reported on migrant population. While experts representing all 17 autonomous communities were contacted to obtain HCV prevalence data among the study population, only Madrid and Navarra were able to provide data appropriate for the analysis (one dataset and one article, respectively). The authors identified two additional studies through reviewing the references of articles included from the original search string, yielding a total of 26 data sources – 25 articles and one dataset (Table 1).^{18,30–53}

Eleven of the 26 studies were conducted on general migrant populations (primary care centres, maternity wards, community-level facilities, blood banks), 9 were in the hospital-based category and 6 were conducted in high-risk population groups.

The literature included data from 8 of the 17 Spanish autonomous communities (Andalusia, Aragon, Castille-La Mancha, Castille-Leon, Catalonia, Galicia, Madrid and Valencia). Fifteen of the 20 data sources based in specific communities were from Catalonia or Madrid, and the majority of HCV screenings were conducted in Catalonia (11,288), Madrid (8173) and Valencia (911).

HCV prevalence among migrants in the general migrant population was 1.6% (95% CI: 0.8–2.7, *I*² = 92.0%) and 4.1% (95% CI: 1.7–7.6, *I*² = 98.7%) in the hospital-based category. The prevalence among high-risk populations was 4.2% (95% CI: 1.2–8.7; *I*² = 97.0%) (Table 2).

We derived prevalence for HCV infection in migrants originating from the following regions: Asia (0.0%; 95% CI: 0–0.8), Europe (7.1%; 95% CI: 2.2–14.2), Latin America (0.9%; 95% CI: 0.2–1.8), North Africa (1.6%; 95% CI: 0.2–4.0) and sub-Saharan Africa (3.6%; 95% CI: 1.5–6.4) (Fig. 2). Pooled prevalences are reported for all regions-of-origin data because of the high heterogeneity among studies.

In the high-risk group, European migrants had the highest prevalence (26.4%; 95% CI: 20.0–33.3). In the hospital-based group, sub-Saharan African (4.1%; 95% CI: 0.7–9.9) and European migrants (3.6%; 95% CI: 0.0–14.1) had the highest prevalences, respectively.

The same pattern was observed in studies conducted among the general migrant population, where the highest prevalences were found among sub-Saharan African (3.1%; 95% CI: 1.5–5.2), European (2.9%; 95% CI: 0.3–7.2) and North African (2.1%; CI: 0.2–5.5) migrants (Table 3).

Discussion

This is the first meta-analysis of HCV prevalence in migrant populations in Spain. The findings indicate that 1.6% of migrants from the general migrant population living in Spain are HCV-antibody positive. In our study, the highest prevalence of HCV was found among migrants from countries in Europe (7.1%) and from sub-Saharan Africa (3.6%). The HCV antibody prevalence of the general migrant population was consistent with previous findings^{11,54} and was found to be same as the estimated prevalence of the general population in Spain.^{23,55} We report an approximate 1.6% anti-HCV prevalence for the general Spanish population on the basis of evidence published by the European Centre for Disease Control and Prevention²³ and similar prevalences reported in Hope et al.'s 2014 article.⁵⁵ However, the abstract of a yet-unpublished cross-sectional study conducted in Santander, Madrid and Valencia has reported the anti-HCV prevalence among the general Spanish population to be 1.1%, substantially lower than previous findings.⁵⁶ Moreover, some studies conducted in subnational areas (e.g., Madrid²⁰ and Navarra³²) also observed lower prevalence rates among the native population than the foreign-born population. Due to conflicting evidence, it is difficult to accurately estimate HCV prevalence in the general population in Spain, and therefore difficult to determine whether all or some migrant populations are at heightened risk for HCV. We have only found one other systematic review estimating the prevalence of HCV in Spain in migrant populations. However, that study did not perform a meta-analysis, and could not estimate the HCV prevalence among migrants in Spain.¹⁹

One study observed that older native-born Spaniards are at greater risk for HCV infection than younger ones.⁵⁷ Because migrants to Spain tend to be younger than the native population, further research investigating differences in HCV prevalence should take age into account.⁵⁸ As has been suggested elsewhere, prevalence estimates should be ideally segregated by age group or birth cohort.⁵⁹

We have chosen to regard the prevalence for the general migrant population as the overall pooled prevalence for all migrants in Spain. Hospital-based studies (e.g., those migrants tested in hospitals and tropical medicine clinics) as well as migrants from high-risk groups may overestimate the HCV prevalence in the studies we included. Hospitalised patients tend to have different characteristics compared with general population.

Our study found that the overall HCV antibody prevalence among migrants tested at hospital level (4.1%) was similar to prevalence in the high-risk migrant group (4.2%). Other studies of native-born high-risk groups in Spain have observed HCV prevalence rates as high as 60% to 80%⁶⁰ – substantially greater than the high-risk group prevalence this study reports for migrants. However, most of those studies were undertaken in people who inject drugs, while none of the studies included in this review specifically sought to enrol migrants who inject drugs. Instead, the high-risk groups in these studies are sex workers,³⁹ prisoners and people living with HIV.^{35,49} Studies conducted among sex workers and HIV-positive sex workers in Spain have found similar, though slightly higher, HCV prevalences. The HCV prevalence among the general prison population in Spain is also similar to the prevalence we found for high-risk migrant populations.⁶¹ The amount of available data on these groups is quite small, however, and the existing studies are outdated.^{61,62} Future Spanish studies should focus on

Table 1
Characteristics of included studies (n = 26).

First author, year of publication	Study region (Spain)	Study period	Study methodology	Study sample	Median age (years)	HCV antibody prevalence (%)
Aguinaga et al., 2017	Navarra	2014–2016	Observational	Migrant in Navarra	–	10/983 (1.02%)
Belhassen-García et al., 2015	Salamanca	January 2007–December 2011	Observational	Migrant minors attending a tropical medicine unit	12.4	8/346 (2%)
Bottecchia et al., 2011	Madrid	January 2007–December 2008	Retrospective observational	Foreigners referred to an infectious diseases department	51.5	212/1718 (12.3%)
Castellà-Dagà et al., 2009	Catalonia	2004–2006	Cross-sectional descriptive	All migrants	33.85	25/2636 (0.95%)
Caro-Murillo et al., 2009	Multiple regions	2004–2006	Observational	Patients with HIV in a hospital setting	36	78/714 (10.92%)
Cuenca-Gómez et al., 2016	Andalusia	2004–2015	Retrospective observational	Patients attended in a Tropical Medicine Unit	31.3	68/505 (2.7%)
Gimeno et al., 2006	Madrid	December 2001–May 2003	Cross-sectional descriptive observational	Migrants in primary care setting	32.7	5/235 (2.12%)
Gutierrez et al., 2004	Madrid	1998–2003	Observational	Newly arrived migrant sex workers (≤ 3 months)	27	11/1484 (0.7%)
Hladun et al., 2014	Barcelona	February 2001–February 2005	Cross-sectional observational	Migrants from low- and middle-income countries	–	41/1248 (3.3%)
López-Olmos et al., 2013	Valencia	2009	Cross-sectional observational	Women with STIs or genital disorders	34.74	0/131 (0%)
Llenas et al., 2012	Madrid	1992–2009	Retrospective observational	HIV patients attended in an outpatient clinic in Madrid	34.3	28/366 (7.7%)
Madrid dataset	Madrid	2008	Serosurvey observational	Migrants	–	11/927 (1.2%)
Manzardo et al., 2008	Catalonia	2001–2004	Observational	Migrants attending a tropical medicine unit	28	57/1848 (3.08%)
Masvidal Aliberch et al., 2010	Catalonia	December 2005–December 2006	Multicentric cross-sectional observational	Newly arrived children (≤ 1 year)	6 months to 15 years	1/1055 (0.1%)
Martín-Ibáñez et al., 2006	Barcelona	2003–2004	Observational	Infants born to migrant women and their mothers	–	11/1414 (0.8%)
Monge-Maillo et al., 2015	Madrid	2000–2009	Observational	Migrants from Latin America and sub-Saharan Africa	29	15/667 (2.24%)
Olivan-Gonzalvo et al., 2004	Zaragoza	January 2000–December 2003	Observational	Adolescents in protection centres in Zaragoza	11.8	1/184 (0.5%)
Pérez-Molina et al., 2010	Multiple regions	1997–2006	Observational	Migrants with HIV attending a tropical medicine referral unit	30	104/1529 (6.80%)
Ramos et al., 2011	Valencia	2001–2010	Observational	Migrants attending the infectious disease unit of a hospital	31	41/780 (5.26%)
Rivas et al., 2013	Madrid	January 2002–December 2008	Cross-sectional observational	Equatorial Guinean and other African migrants attending a tropical medicine unit	39	236/1496 (15.78%)
Saiz de la Hoya et al., 2013	Several regions	June 2008	Cross-sectional observational	Prisoners	–	3/146 (2.1%)
Santiago et al., 2011	Madrid	August 2007–October 2008	Retrospective observational	Migrant pregnant women attended in an antenatal care Unit	28.6	12/1297 (0.9%)
Serre-Del Cor et al., 2016	Barcelona	January 2009–December 2012	Retrospective observational	Sub-Saharan migrant	17	2/167 (1.2%)
Soler-González et al., 2012	Lleida	2007	Multicentric descriptive observational	Migrants attending at primary care and hospital level	33.5	33/1803 (1.8%)
Toro et al., 2006	4 regions: Madrid, Barcelona, Pontevedra and Toledo	January 2002–April 2003	Observational	Newly arrived migrants (≤ 2 years)	29.5	37/1303 (2.9%)
Valerio et al., 2008	Catalonia	April 2006–April 2007	Prospective observational	Newly arrived migrants (≤ 5 years)	33.7	43/710 (6.1%)

Table 2
Pooled HCV antibody prevalence, heterogeneity and variation measurements for migrants in Spain, by risk category.^a

Risk category	HCV antibody-positive	Screened	HCV antibody prevalence (%)	Confidence interval (95%)	Heterogeneity I^2 (%)
General migrant population	191	10,055	1.6	(0.8–2.7)	92.0
Elevated-risk groups	690	13,621	4.1	(1.7–7.6)	98.7
High-risk groups	226	4406	4.2	(1.2–8.7)	97.0

^a Random-effect pooled prevalences are reported for all studies.




Fig. 2. Forest plot of HCV antibody prevalence (%) among migrant groups by region of origin and study authors.

Table 3

Pooled HCV antibody prevalence, heterogeneity and variation measures for migrants in Spain, by region of origin and risk category.

Region of origin	High-risk groups (%), (95% CI)	Elevated-risk groups (%), (95% CI)	General migrant population (%), (95% CI)	Heterogeneity I^2 (%)
Asia	0.0	1.0 (0.1–2.8) ^a	0.8 (0.0–4.5)	84.6
Europe	26.4 (20.0–33.3) ^a	3.6 (0.0–14.1)	2.9 (0.3–7.2)	92.7
Latin America	2.5 (0.0–9.5) ^a	1.1 (0.3–2.4)	0.2 (0.0–0.5) ^a	82.9
North Africa	20.3 (8.8–34.4) ^a	0.3 (0.0–0.8) ^a	2.1 (0.2–5.5)	86.9
Sub-Saharan Africa	5.5 (1.7–11.0)	4.1 (0.7–9.9)	3.1 (1.5–5.2) ^a	94.5

^a These values report random-effect pooled prevalences. Fixed-effect pooled prevalences are reported for all other values.

groups at high risk for HCV, such as people who inject drugs, sex workers, people living with HIV and prisoners.

We found that migrants from certain regions were underrepresented in our pooled sample. Strikingly, migrants from Europe constituted only 5.6% of the sample, yet they comprise 35% of Spain’s migrant population.⁷ Although it was not possible to determine the HCV prevalence for Eastern and Western European migrants separately in most risk categories, European migrants in our study had the highest HCV antibody prevalence of all migrant groups. That was especially true of high-risk groups, where Europeans co-infected with HIV had the highest prevalence (26.4%). This prevalence was calculated using only two studies with limited sample size,^{30,35} so its statistical power is limited. Moreover, high-risk groups might be overrepresented and this data might not be representative of the whole European migrant population in Spain. Unfortunately, we could not find data about HCV prevalence in those European countries where migrants most frequently come from.

A study by the European Centre for Disease Prevention and Control likewise found sub-Saharan African and Eastern Europeans migrants to have higher prevalences of HCV than any other migrant group in Spain.⁶³ Finally, the aforementioned higher

HCV prevalence among Eastern Europeans co-infected with HIV should be considered in the light of findings from the WHO Global Hepatitis Report, which presents evidence of higher past or present HCV infection among people living with HIV in Eastern Europe than those in any other region.⁹

Studies elsewhere in Europe have also found that European migrants are at risk for HCV.⁶⁴ However, some European studies systematically exclude migrants originating from other European countries,⁶⁵ making the true prevalence of HCV among European migrants more difficult to estimate accurately.

There are also few data on Asian migrants (4% of the sample). Therefore, the low prevalence obtained should be interpreted with caution.

Our study is limited by large gaps in the data on migrants including many older studies; additional research is needed, particularly at the subnational level. We found relevant studies for only eight of the autonomous communities in Spain, and we recognise that our results are not necessarily representative of the Spanish migrant population. The autonomous community of Galicia, for example, has a higher proportion of Brazilian migrants than the national average,⁶⁶ and this population appears to be underrepresented in our meta-analysis.

Anti-HCV testing does not differentiate between current and past HCV infections, and studies using data from anti-HCV tests therefore overestimate the prevalence of chronic HCV.⁶⁷ This review only used data from anti-HCV tests, because only three of the included studies reported HCV RNA results along with HCV antibody prevalence.^{18,33,52} As HCV can be cured by antiviral treatment or the body's own immune response, our sample likely greatly overestimated the prevalence of extant HCV disease among migrants in Spain. This overestimation is another limitation of this study and future studies should include RNA testing results, if possible.

Eleven of our 26 data sources were not disaggregated by region of origin, and those that were generally were not further separated by country of origin. This prevented us from analysing country of origin as a risk factor for HCV, which is particularly important in the Asian region due to large difference of prevalence across countries. Furthermore, pooled estimates do not capture the heterogeneity that exists within regions. Migrants from different countries in the same region can have large variation in HCV prevalence, as can national populations within a region.⁶⁸

All these limitations are due to the limited data available, and therefore results should be interpreted with caution.

The lack of high-quality data on migrants and health remains a widespread challenge globally as well. At the 69th World Health Assembly in 2016, the WHO director general characterised the need for better data on the health needs of migrants, refugees and displaced persons as “urgent”. Effective priority-setting to achieve the 2030 Sustainable Development Goals will require countries to have adequate health information systems with robust epidemiological data on migration.⁶⁹ Currently, health information systems at the Spanish subnational level lack the capacity to analyse data based on migration status and/or country of origin. Incongruent migration categorisations, the use of different variables as proxies for migration status (such as nationality, ethnicity and origin), and a frequent lack of data on country of birth all make it extremely difficult to compare migrant health data across different communities. In its European action plan on hepatitis, WHO calls for the linking and integration of viral hepatitis strategic information systems with broader health information systems, and suggests that countries expand the cross-border sharing of information to ensure service continuity for refugees, migrants and other mobile populations.⁷⁰

One important recommendation suggested by our findings concerns HCV testing. As some migrant populations are at higher risk for HCV, testing is a crucial step in linking them to early treatment and care.^{17,23} In 2014, WHO recommended that HCV testing be offered to any high-risk group⁷¹ and two years later the European Association for the Study of the Liver recommended that all at-risk populations, as determined by local epidemiology, be screened for HCV.²⁴ Although screening migrants for hepatitis has been demonstrated to be a cost-effective strategy for controlling the hepatitis B virus (HBV) in some countries,⁷² Spain does not have any national HCV screening recommendations for migrants according to the national HCV strategic plan.²³ At the subnational level, some autonomous communities such as the Canary Islands and Galicia recommend HCV screening for migrants originating from high-prevalence countries,^{73,74} while others do not.^{75–79} WHO further recommends that where migrants may have difficulties accessing sexual and reproductive health services, the prevention of the sexual transmission of viral hepatitis can be better ensured through dedicated services for this population,⁷⁰ and this is another opportunity to provide testing services.

Conclusions

This systematic review found that the estimated HCV antibody prevalence among migrants in Spain is similar to the prevalence

among the native-born population. When segregated by region of origin, HCV prevalence among migrants of European and African origins was higher than the general population. Data were scarce and highly heterogeneous and therefore the results should be interpreted with caution. In spite of this, our meta-analysis provides HCV prevalence estimates that can be used to better understand the burden of HCV in Spain and support the scaling up of HCV testing, linkage to care and treatment in line with the WHO viral hepatitis strategy, which Spain has adopted. Providing Spanish policy-makers and health authorities with better data on HCV prevalence among migrants, including region and country of origin, would help them design effective, targeted interventions in their efforts to eliminate the disease, as set out in the Spanish hepatitis C strategy.

Availability of data and material

The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Funding

This study was partially funded by Gilead Sciences with a grant to ISGlobal, Hospital Clínic, University of Barcelona, Spain. The team is also supported by the Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) (2017 SGR 924) and by the Tropical Disease Cooperative Research Network (RICET) (RD12/0018/0010). ISGlobal is a member of the Centres de Reserca de Catalunya (CERCA) Programme, Government of Catalonia (Spain).

Authors' contribution

JVL conceptualised, designed and coordinated the study. DJB drafted the manuscript and prepared the final manuscript, with input from ARM, JVL, JDA, JGS and JLC. ON designed the search strings and conducted the database search. DJB and ARM performed the systematic review and data extraction. AC performed meta-analysis. All authors read and approved the final manuscript.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgements

The authors would like to acknowledge Kristina Louise Hetherington and Kelly Safreed-Harmon for their copy-editing.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at [doi:10.1016/j.eimc.2018.04.002](https://doi.org/10.1016/j.eimc.2018.04.002).

References

1. Who is a migrant? International Organization for Migration. <https://www.iom.int/who-is-a-migrant> [accessed 15.03.17].
2. Lee ES. A theory of migration. *Demography*. 1966;3:47–57.
3. Key migration terms. International Organization for Migration. <https://www.iom.int/key-migration-terms> [accessed 15.03.17].
4. Migration and migrant population statistics. Eurostat Statistics Explained. http://ec.europa.eu/eurostat/statistics-explained/index.php/Migration_and_migrant_population_statistics [accessed 09.05.17].
5. World migration report 2015. International Organization for Migration; 2015.
6. Migration and migrant population statistics. Eurostat statistics explained. http://ec.europa.eu/eurostat/statistics-explained/index.php/Migration_and_migrant_population_statistics [accessed 05.01.17].

7. Press release: population figures at 1 January 2015: migrations statistics 2014. Instituto Nacional de Estadística; 2015. <http://www.ine.es/en/prensa/np917.en.pdf> [accessed 15.03.17].
8. The Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. *Lancet Gastroenterol Hepatol.* 2017;2:161–76.
9. Global Hepatitis Report, 2017. Geneva, Switzerland: World Health Organization; 2017.
10. Hatzakis A, Van Damme P, Alcorn K, Gore C, Benazzouz M, Berkane S. The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conference. *J Viral Hepat.* 2013;20:1–20.
11. European Centre for Disease Prevention and Control. Epidemiological assessment of hepatitis B and C among migrants in the EU/EEA. ECDC technical report. Stockholm, Sweden; 2016.
12. World Health Organization. Global health sector strategy on viral hepatitis 2016–2021. Geneva, Switzerland; 2016.
13. Jakab Z, Severoni S, Ostlin P, Verschuuren M, Stein CE. Refugee and migrant health: a priority in the WHO European Region. *Lancet.* 2015;386:2477–8.
14. Lazarus JV, Mozalevskis A, Safreed-Harmon K, Eramova I. Strengthening HBV and HCV Surveillance in Europe: priorities suggested by the 2013 WHO Policy Survey of Member States and the 2014 Civil Society Survey. *HMAP.* 2016:1–3.
15. Chen DS, Hamoudi W, Mustapha B, Layden J, Nersesov A, Reic T, et al. Strategies to manage hepatitis C virus infection disease burden—Volume 4. *J Viral Hepat.* 2017;24 Suppl. 2:44–63.
16. Guionnet A, Navaza B, Pizarro de la Fuente B, Pérez-Eliás MJ, Dronza F, López-Vélez R, et al. Immigrant women living with HIV in Spain: a qualitative approach to encourage medical follow-up. *BMC Public Health.* 2014;14:1115.
17. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. *J Hepatol.* 2008;48:148–62.
18. Rivas P, Herrero MD, Poveda E, Madejón A, Treviño A, Gutiérrez M, et al. Hepatitis B, C, and D and HIV infections among immigrants from Equatorial Guinea Living in Spain. *Am J Trop Med Hyg.* 2013;88:789–94.
19. Calderón Sandubete E, Yang Lai R, Calero Bernal ML, Martínez Rísquez MT, Calderón Baturone M, Horra Padilla CL. Hepatitis crónicas virales B y C en población inmigrante en España. *Rev Esp Salud Pública.* 2014;88:811–8.
20. García Comas L, Ordobás Gavín M, Sanz Moreno JC, Ramos Blázquez B, Gutiérrez Rodríguez A, Astray Mochales J, et al. Prevalence of hepatitis C antibodies in the population aged 16–80 years in the Community of Madrid 2008–2009. *J Med Virol.* 2015;87:1697–701.
21. Belza MJ, Clavo P, Ballesteros J, Menéndez B, Castilla J, Sanz S, et al. Social and work conditions, risk behavior and prevalence of sexually transmitted diseases among female immigrant prostitutes in Madrid (Spain). *Gac Sanit.* 2004;18:177–83.
22. Pawlowsky JM, Aghemo A, Back D, Dusheiko G, Forns X, Puoti M, et al. EASL recommendations on treatment of hepatitis C 2016. European Association for the Study of the Liver; 2016.
23. Plan Estratégico Para El Abordaje de la Hepatitis C en el Sistema Nacional de Salud. Ministerio de Sanidad, Servicios Sociales e Igualdad Migration. https://www.msssi.gob.es/ciudadanos/enfLesiones/enfTransmisibles/docs/plan_estrategico_hepatitis_C.pdf [accessed 15.03.17].
24. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting, Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA.* 2000;283:2008–12.
25. Quality assessment tool for observational cohort and cross-sectional studies (online). National Heart, Lung, and Blood Institute. National Institutes of Health. <https://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/cohort> [accessed 21.02.17].
26. Freeman MF, Tukey JW. Transformations related to the angular and the square root. *Ann Math Stat.* 1950;21:607–11.
27. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials.* 1986;7:177–88.
28. Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G, et al. Methods to estimate the between-study variance and its uncertainty in meta-analysis. *Res Synth Methods.* 2016;7:55–79.
29. StataCorp. Stata statistical software: release 15. College Station, TX: StataCorp LP; 2017.
30. Llenas-García J, Rubio R, Hernando A, Fiorante S, Maseda D, Matarranz M, et al. Clinico-epidemiological characteristics of HIV-positive immigrants: study of 371 cases. *Enferm Infecc Microbiol Clin.* 2012;30:441–51.
31. Santiago B, Blázquez D, López F, Sainz T, Muñoz M, Alonso T, et al. Serological profile of immigrant pregnant women against HIV, HBV, HCV, rubella, *Toxoplasma gondii*, *Treponema pallidum*, and *Trypanosoma cruzi*. *Enferm Infecc Microbiol Clin.* 2012;30:64–9.
32. Aguinaga A, Díaz-González J, Pérez-García A, Barrado L, Martínez-Baz I, Casado I, et al. The prevalence of diagnosed and undiagnosed hepatitis C virus infection in Navarra, Spain, 2014–2016. *Enferm Infecc Microbiol Clin.* 2017 [Epub ahead of print].
33. Belhassen-García M, Pérez Del Villar L, Pardo-Lledias J, Gutiérrez Zufiaurre MN, Velasco-Tirado V, Cordero-Sánchez M, et al. Imported transmissible diseases in minors coming to Spain from low-income areas. *Clin Microbiol Infect.* 2015;21:370.
34. Bottecchia M, Madejón A, Puente S, García-Samaniego J, Rivas P, Herrero D, et al. Detection of hepatitis B virus genotype A3 and primary drug resistance mutations in African immigrants with chronic hepatitis B in Spain. *J Antimicrob Chemother.* 2011;66:641–4.
35. Caro-Murillo AM, Gutiérrez F, Manuel Ramos J, García-Samaniego J, Rivas P, Herrero D, et al. Infección por virus de la inmunodeficiencia humana en inmigrantes en España: características epidemiológicas y presentación clínica en la cohorte CoRIS, 2004–2006. *Enferm Infecc Microbiol Clin.* 2009;27:380–8.
36. Castellà Daga I, Ibáñez Masferrer M, Quesada Sabaté M, Igual Masalles E. Progress in the detection of hepatitis B and C virus in the immigrant community. *Aten Primaria.* 2009;41:352–3.
37. Serre Delcor N, Maruri BT, Arandes AS, Guiu IC, Essadik HO, Soley ME, et al. Infectious diseases in sub-Saharan immigrants to Spain. *Am J Trop Med Hyg.* 2016;94:750–6.
38. Gimeno Feliu LA. Health examination of immigrants in primary care. *Enferm Emergentes.* 2006;8:40–7.
39. Gutiérrez M, Tajada P, Alvarez A, De Julián R, Baquero M, Soriano V, et al. Prevalence of HIV-1 non-B subtypes, syphilis, HTLV, and hepatitis B and C viruses among immigrant sex workers in Madrid, Spain. *J Med Virol.* 2004;74:521–7.
40. Hladun O, Grau A, Esteban E, Jansá JM. Results from screening immigrants of low-income countries: data from a public primary health care. *J Travel Med.* 2014;21:92–8.
41. López-Olmos J. Mujeres inmigrantes versus autóctonas, Diferencias en disfunciones sexuales, infecciones vaginales y lesiones cervicales. *Clin Invest Gin Obst.* 2013;40:242–52.
42. Manzardo C, Treviño B, Prat JG, Cabezas J, Monguí E, Clavería I, et al. Communicable diseases in the immigrant population attended to in a tropical medicine unit: epidemiological aspects and public health issue. *Travel Med Infect Dis.* 2008;6:4–11.
43. Martín Ibáñez I, Vilchez L, Blasco JL, Mur Sierra A. Resultados perinales de las gestantes inmigrantes. *An Pediatr (Barc).* 2006;64:550–6.
44. Masvidal Aliberch RM, Estabanell Buxó A, Miguel Gil B, Cruz Rodríguez C, de Frutos Gallego E, Guzmán Molina C, et al. Indication of determination of antibodies against hepatitis C and A viruses in the protocol for the care of young immigrants. *Gac Sanit.* 2010;24:288–92.
45. Monge-Maíllo B, López-Vélez R, Norman FF, Ferrere-González F, Martínez-Pérez Á, Pérez-Molina JA. Screening of imported infectious diseases among asymptomatic sub-Saharan African and Latin American immigrants: a public health challenge. *Am J Trop Med Hyg.* 2015;92:848–56.
46. Oliván-Gonzalvo G. Prevalence of hepatitis B, hepatitis C, HIV and latent tuberculosis infection and syphilis in a population of immigrant children at high social risk. *Enferm Infecc Microbiol Clin.* 2004;22:250.
47. Pérez-Molina JA, López-Vélez R, Navarro M, Pérez-Eliás MJ, Moreno S. Clinicoepidemiological characteristics of HIV-infected immigrants attended at a tropical medicine referral unit. *J Travel Med.* 2009;16:248–52.
48. Ramos JM, Masía M, Padilla S, Escolano A, Bernal E, Gutiérrez F. Enfermedades importadas y no importadas en la población inmigrante, Una década de experiencia desde una unidad de enfermedades infecciosas. *Enferm Infecc Microbiol Clin.* 2011;29:185–92.
49. Saiz de la Hoya P, Marco A, García-Guerrero J, Rivera A, Prevalhep Study Group. Hepatitis C and B prevalence in Spanish prisons. *Eur J Clin Microbiol Infect Dis.* 2011;30:857–62.
50. Cuenca-Gómez JA, Salas-Coronas J, Soriano-Pérez MJ, Vázquez-Villegas J, Lozano-Serrano AB, Cabezas-Fernández MT. Viral hepatitis and immigration: a challenge for the healthcare system. *Rev Clin Esp.* 2016;216:248–52.
51. Soler-González J, Real J, Farré J, Serna C, Cruz I, Ruiz C, et al. Comparative analysis of serological tests performed in immigrants in the Lleida health area. *Aten Primaria.* 2013;45:84–91.
52. Toro C, Jiménez V, Rodríguez C, Del Romero J, Rodés B, Holguín A, et al. Molecular and epidemiological characteristics of blood-borne virus infections among recent immigrants in Spain. *J Med Virol.* 2006;78:1599–608.
53. Valerio LI, Barro S, Pérez B, Roca C, Cruz I, Fernández J, Solsona L. Seroprevalence of chronic viral hepatitis markers in 791 recent immigrants in Catalonia, Spain. Screening and vaccination against hepatitis B recommendations. *Rev Clin Esp.* 2008;208:426–31.
54. Huerga Aramburu H, López-Vélez R. Estudio comparativo de la patología infecciosa en niños inmigrantes de distintas procedencias. *An Pediatr (Barc).* 2004;60:16–21.
55. Hope VD, Eramova I, Capurro D, Donoghoe MC. Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. *Epidemiol Infect.* 2014;142:270–86.
56. Lavin AC, Perello C, Llerena S, Gomez M, Escudero MD, Rodriguez L, et al. Prevalence of hepatitis C in the Spanish population, the prevhep study (ethon cohort). In: AEEH conference 2017. Oral presentation. 15.42–15.54. 2017.
57. Solà R, Cruz De Castro E, Hombrados M, Planas R, Coll S, Jardí R, et al. Prevalence of hepatitis B and hepatitis C viruses in different counties of Catalonia, Spain: cross-sectional study. *Med Clin (Barc).* 2002;119:90–5.
58. Estadística del Padrón Continuo a 1 de enero de 2016. Datos a nivel nacional, comunidad autónoma y provincia. Población y Edad Media por nacionalidad y sexo. Instituto Nacional de Estadística; 2016. <http://www.ine.es/jaxi/Datos.htm?path=/t20/e245/p04/a2016/10/&file=00000010.px> [accessed 06.05.17].
59. Lazarus JV, Bromberg DJ. Commentary on Trias-Llimós et al. (2017): birth cohort research—an essential tool to guide public health interventions. *Addiction.* 2017;112:259–60.
60. Roncero C, Littlewood R, Vega P, Martínez-Raga J, Torrens M. Chronic hepatitis C and individuals with a history of injecting drugs in Spain: population assessment, challenges for successful treatment. *Eur J Gastroenterol Hepatol.* 2017 [Epub ahead of print].

61. Marco A, Gallego C, Caylà JA. Incidence of hepatitis C infection among prisoners by routine laboratory values during a 20-year period. *PLOS ONE*. 2014;9:e90560.
62. Pineda JA, Aguado I, Rivero A, Vergara A, Hernández-Quero J, Luque F, et al. HIV-1 infection among non-intravenous drug user female prostitutes in Spain, no evidence of evolution to pattern II. *AIDS*. 1992;6:1365–9.
63. European Centre for Disease Prevention and Control. Assessing the burden of key infectious diseases affecting migrant populations in the EU/EEA; 2014.
64. Carballo M, Maclean EC, Gudumac I, Van Damme P. Hepatitis C and migration: a public health challenge. *J Fam Med*. 2016;3:1065.
65. Urbanus AT, van de Laar TJ, van den Hoek A, Zuure FR, Speksnijder AG, Baaten GG, et al. Hepatitis C in the general population of various ethnic origins living in the Netherlands: should non-Western migrants be screened? *J Hepatol*. 2011;55:1207–14.
66. Avance de Galicia 08 en La Habana. Xunta de Galicia; 2008.
67. Tillman HL. Hepatitis C virus core antigen testing: role in diagnosis, disease monitoring and treatment. *World J Gastroenterol*. 2014;20:6701–6.
68. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. *J Hepatol*. 2014;61 Suppl.:45–57.
69. World Health Organization. WHA 69: technical briefing on migration and health. <http://who.int/migrants/publications/WHA69.mh-technical-briefing.pdf> [accessed 09.05.17].
70. World Health Organization Regional Office for Europe. Action plan for the health sector response to viral hepatitis in the WHO European Region. Copenhagen, Denmark; 2016.
71. World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. Geneva; 2014.
72. Hahné SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminen M, Laar Mv. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. *BMC Infect Dis*. 2013;13.
73. Xunta de Galicia Consellería de Sanidade. Guía de Práctica Clínica Hepatitis C. Santiago de Compostela, Spain; 2014.
74. Plan de Prevención de la Infección por Hepatitis en Canarias. Servicio Canario de la Salud – Gobierno de Canarias. http://www3.gobiernodecanarias.org/sanidad/scs/content/1de5a551-46de-11e3-a0f565699e4ff786/Plan.HepC_Canarias_Completo.pdf [accessed 15.03.17].
75. Guia per a la prevenció i el control de l'hepatitis C. Departament de Salut Catalunya; 2015. http://canalsalut.gencat.cat/web/.content/home_canal_salut/professionals/temes_de_salut/infeccions_de_transmissio_sexual/documents/guiahepatitisc.pdf [accessed 15.03.17].
76. Protocolos de actuación frente a enfermedades infecciosas, hepatitis C. Gobierno Vasco Departamento de Sanidad; 2004. https://www.osakidetza.euskadi.eus/contenidos/informacion/vigilancia_protocolos/es.def/adjuntos/Hepatitis%20C%20CASTELLANO.PDF [accessed 15.03.17].
77. Generalitat de Valencia Conselleria de Sanitat. Valencia: Guía de Actuación Clínica; 2004.
78. Junta de Andalucía. Protocolo de Vigilancia y Alerta de Hepatitis C. Seville; 2016.
79. Comisión de Sanidad Cortes de Aragón. Plan Estratégico de Manejo y Control de la Hepatitis C en la Comunidad Autónoma de Aragón. Zaragoza; 2016.